Over the past couple of days there has been news of several multi-billion dollar deals in the pharmaceutical sector.
The big news came on Monday night when it began to leak that Valeant Pharmaceuticals (NYSE:VRX) was going to make a bid for Allergan (NYSE:AGN), the maker of Botox. The deal could be worth as much as $47 billion in cash and stock. The share price of both stocks soared on the news.
This weekend there was a rumor that Pfizer (NYSE:PFE) could make a bid for AstraZeneca (NYSE:AZN) that would make it one of the largest deals in the sector, upwards of $100 billion. And then there was Novartis (NYSE:NVS) buying the oncology unit at GlaxoSmithKline (NYSE:GSK) for over $15 billion.
The flurry of M&A activity has helped the sector rebound from a nasty sell-off that was led by the biotech stocks over the last month. The moves over the last few days show the strength of the sector and the cash that is available for even more mergers in the future.
When there is M&A activity in a sector it typically creates excitement and it attracts new money. This trend will help all pharma-related ETFs. The iShares U.S. Pharmaceutical ETF (NYSEARCA:IHE) has exposure to Pfizer and Allergen, with both stocks in the top six holdings. In the last 12 months the ETF is up 26.5 percent and it charges an expense ratio of 0.45 percent.
The SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) also has AGN and PFE in its top holdings at number two and number nine, respectively. The ETF is up 42 percent in the last year and it charges an expense ratio of 0.35 percent.
The Market Vectors Pharmaceutical ETF (NYSEARCA:PPH) is different than the first two listed because it invests in companies outside of the U.S. Therefore, the ETF can hold more of the stocks mentioned in the merger activity. Similar to the first two ETFs, Allergen and Pfizer are in the top six holdings, but it also owns Novartis, AstraZeneca, GlaxoSmithKline and Valeant. The expense ratio is 0.35 percent and over the last 12 months it was up 25.4 percent.
Expect the ETFs to be on the move this week and possibly retest the highs set earlier this year.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Disclaimer: Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.